Study on the Safety and Effectiveness of Adalimumab and Etanercept in Children with Active Juvenile Idiopathic Arthritis

3 1 1 1

What is this study about?

This clinical trial is focused on studying the treatment of Juvenile Idiopathic Arthritis (JIA), a condition that causes joint inflammation in children. The study involves two medications: Adalimumab and Etanercept. These medications are known as anti-TNF drugs, which help reduce inflammation by blocking a protein called tumor necrosis factor (TNF) that contributes to inflammation in the body. The trial will compare the original versions of these medications with their biosimilar versions. Biosimilars are medications that are very similar to the original product but are not identical, and they are often more affordable.

The purpose of the study is to evaluate the safety and effectiveness of switching between the original and biosimilar versions of these medications in children with JIA who are in clinical remission, meaning their disease activity is low or inactive. Participants in the study will be randomly assigned to receive either the original or biosimilar version of the medication. The study will last for a total of 18 months, during which the participants’ health and response to the medication will be monitored closely.

Throughout the study, the main goal is to see how many children remain in clinical remission after switching between the original and biosimilar medications. This will help determine if the biosimilar versions are as effective and safe as the original medications. The study aims to provide valuable information that could help improve treatment options for children with Juvenile Idiopathic Arthritis.

1 joining the study

Upon joining the study, the patient is confirmed to have Juvenile Idiopathic Arthritis (JIA) and meets the criteria for participation. This includes being between the ages of 2 and 18, having moderate to high disease activity despite previous treatment, and meeting specific weight requirements for certain medications.

2 initial treatment phase

The patient begins treatment with either adalimumab or etanercept. Adalimumab is administered as a solution for injection in a pre-filled syringe, while etanercept is provided as a powder and solvent for solution for injection. The specific dosage and frequency are determined based on the patient’s weight and medical condition.

3 monitoring and assessment

Throughout the study, the patient’s response to the medication is closely monitored. This includes regular assessments to evaluate the effectiveness of the treatment and any potential side effects. The goal is to achieve clinical remission, defined as a state of inactive disease for at least six months.

4 switching phase

After an initial period, the patient may be switched from the original medication to a biosimilar version, or vice versa. This phase is designed to compare the safety and efficacy of the original and biosimilar medications.

5 final assessment

At the end of the study, the patient’s condition is evaluated to determine the overall effectiveness of the treatment strategy. The primary endpoint is achieving clinical remission at 18 months, with a focus on comparing outcomes between those who switched medications and those who did not.

Who Can Join the Study?

Children diagnosed with Juvenile Idiopathic Arthritis (JIA) according to specific criteria, who are candidates for treatment with certain medications called anti-TNF alpha drugs (etanercept or adalimumab).
Children must have moderate to high disease activity even after taking a medication called methotrexate for at least 3 months.
Children must be between the ages of 2 and less than 18 years old at the time they join the study.
For those taking Etanercept, only children who meet specific weight requirements can join. This is because the medication comes in fixed doses. Children must weigh more than 30 kg and less than 32 kg, or more than 62 kg.
Children and their parents must be able to follow all the study procedures and communicate effectively with the study staff.
Parents must provide written consent, which means they agree to let their child participate in the study after understanding all the details.
If the child is sexually active, they must agree to use highly effective birth control methods during the study.

Who Cannot Join the Study?

Patients who are not in clinical remission. This means their disease is not currently under control or showing no symptoms.
Patients who are not currently on anti-TNF medication. These are specific drugs used to reduce inflammation in conditions like arthritis.
Patients who have not been previously treated with adalimumab or etanercept. These are specific medications used to treat arthritis.
Patients who have any other medical conditions that might interfere with the study or the treatment.
Patients who are unable to follow the study procedures or attend the required visits.
Patients who are participating in another clinical trial at the same time.
Patients who have a history of allergic reactions to the study medications.
Patients who are pregnant or breastfeeding.

Where you can join this trial?

Verified and Recommended Sites

No sites found in this category

Verified Sites

Site Name	City	Country	Status
Azienda Ospedaliera Universitaria Universita’ Degli Studi Della Campania Luigi Vanvitelli	Naples	Italy
Azienda Ospedaliera Universitaria Federico II Di Napoli	Naples	Italy

Other Sites

Site Name	City	Country
Ospedale Vito Fazzi Lecce	Lecce	Italy
Azienda Ospedaliero-Universitaria Policlinico G. Rodolico-San Marco Di Catania	Catania	Italy
IRCCS Istituto Giannina Gaslini	Genoa	Italy
Azienda Ospedaliera Universitaria Meyer IRCCS	Florence	Italy
Asst Centro Specialistico Ortopedico Traumatologico Gaetano Pini Cto	Milan	Italy
ARNAS Civico Di Cristina Benfratelli	Palermo	Italy
Istituto Di Ricovero E Cura A Carattere Scientifico Materno Infantile Burlo Garofolo	Trieste	Italy
Azienda Ospedaliera di Padova	Padua	Italy
Fondazione IRCCS Ca Granda Ospedale Maggiore Policlinico	Milan	Italy
A.O.U. Policlinico G. Martino Di Messina	Messina	Italy
Universita Degli Studi Di Brescia	Brescia	Italy
Ospedale Pediatrico Bambino Gesu’	Rome	Italy
Agcpqwt Uhqeu Szjfkuafa Ldrpda Dz Bjlcmth	Bologna	Italy
Ujzgghviiz Mpznf Gbihdyi Ou Cspxzlqgj	Catanzaro	Italy

Trial status

Country	Status	Recruitment Start
Italy	Not recruiting	18.10.2022

Trial locations

Investigated drugs:

Adalimumab is a medication used to reduce inflammation in the body. It is commonly used to treat conditions like Juvenile Idiopathic Arthritis (JIA) by blocking a protein called TNF-alpha, which is involved in inflammatory processes. In this trial, the effectiveness and safety of switching from the original adalimumab to its biosimilar version, and vice versa, are being evaluated.

Etanercept is another medication that helps manage inflammation by targeting the TNF-alpha protein. It is used to treat autoimmune conditions such as Juvenile Idiopathic Arthritis. The trial is assessing the safety and efficacy of switching between the original etanercept and its biosimilar counterpart in children who are in clinical remission from JIA.

Investigated diseases:

Juvenile idiopathic arthritis

Juvenile Idiopathic Arthritis – This is a type of arthritis that occurs in children under the age of 16. It is characterized by persistent joint inflammation, which can lead to pain, swelling, and stiffness. The disease can affect one or multiple joints and may also cause symptoms such as fever and rash. Over time, it can lead to joint damage and growth problems if not managed properly. The exact cause is unknown, but it is believed to involve a combination of genetic and environmental factors. The progression of the disease can vary, with some children experiencing symptoms for only a few months, while others may have symptoms for many years.

Trial ID:

2024-515557-22-00

Trial Phase:

Therapeutic confirmatory (Phase III)

Other Trials to Consider

#1 Clinical Trials Search in Europe

Study on the Safety and Effectiveness of Adalimumab and Etanercept in Children with Active Juvenile Idiopathic Arthritis

What is this study about?

Who Can Join the Study?

Who Cannot Join the Study?